<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052491</url>
  </required_header>
  <id_info>
    <org_study_id>SC100+ Clinical #1</org_study_id>
    <nct_id>NCT03052491</nct_id>
  </id_info>
  <brief_title>Effects of a 10 Component Dietary Supplement on Health and the Quality of Life</brief_title>
  <official_title>Effects of a Multi-Pathway Dietary Supplement (Stem Cell 100+) on Indices of Health and Life Expectancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centagen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centagen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label field trial evaluates the effects of treatment with a multi-pathway dietary
      supplement (Stem Cell 100+) that has been commercially available for several years. The
      objective of the intervention trial is to determine if normal subjects over 35 years of age
      experience any observable health benefits from the dietary supplement as to their blood
      pressure, pulse rate, blood cholesterol, lung capacity, stress levels, or self reported
      changes in markers of overall health and life expectancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, only dietary restriction has been verified to slow the rate of aging and to
      promote general health. This trial is designed to see whether a complex supplement (Stem Cell
      100+) that targets multiple longevity pathways could also have positive effects on several
      markers of successful aging and good health. Multipath causes of aging include: stem cell
      function, telomere loss, chronic stress, inflammation, insulin-like growth factors,
      autophagy, vascular loss, neural dysfunction, and oxidative stress. The goal of the study was
      to test the effects of this novel multipath intervention strategy in a clinical trial of
      healthy people using health markers such as blood pressure, cholesterol status, lung
      function, stress levels, and self-reported health status. Hundreds of published animal and
      human clinical studies have been done with each of the individual active ingredients in the
      formulation, which target many critical causes of aging.

      Based on their published animal studies showing extension of life span in a model animal and
      their laboratory work on adult human stem cells, the investigators believe that Stem Cell
      100+ will provide evidence of efficacy in addressing multiple index markers of health and
      life expectancy outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2016</start_date>
  <completion_date type="Actual">August 24, 2016</completion_date>
  <primary_completion_date type="Actual">August 24, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label field trial without a placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline and at an average of 15 weeks</time_frame>
    <description>Change in Systolic and Diastolic Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>Baseline and at an average of 15 weeks</time_frame>
    <description>Change in HDL Cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Capacity</measure>
    <time_frame>Baseline and at an average of 15 weeks</time_frame>
    <description>Change in Peak Expiatory Flow</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress Level</measure>
    <time_frame>Baseline and at an average of 15 weeks</time_frame>
    <description>Change in Heart Rate Variability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline and at an average of 15 weeks</time_frame>
    <description>Change in Heart Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Health</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Concentrate or Focus</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Flexibility</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Relax</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold/Flu Resistance</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress Tolerance</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy Level</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endurance</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Walking</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climbing Stairs</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mood</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitality</measure>
    <time_frame>From baseline through study completion, an average of 15 weeks</time_frame>
    <description>Self-Reported Change based on a 7 point range from Much Better (+3) to Much Worse (-3)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Blood Pressure</condition>
  <condition>HDL Low</condition>
  <condition>Stress</condition>
  <condition>Lung Function Decreased</condition>
  <condition>Quality of Life</condition>
  <condition>Energy Supply; Deficiency</condition>
  <condition>Concentration Ability Impaired</condition>
  <condition>Joint Instability</condition>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Stem Cell 100+ Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stem Cell 100+</intervention_name>
    <description>Open-Label 10-Component Dietary Supplement</description>
    <arm_group_label>Stem Cell 100+ Intervention</arm_group_label>
    <other_name>SC100+</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No history of serious cardiovascular, cancer, or neural disease.

          -  Normal health for age

          -  Willing to have blood drawn at baseline and after trial

          -  Willing to submit to evaluation testing of blood pressure, lung testing, stress
             testing.

          -  Willing to take online self reported survey of health at end of trial

        Exclusion Criteria:

          -  History of metastatic cancer, heart attack, dementia, or other life-threatening
             disease

          -  Any subject who is not capable of responding to a self-reported online questionnaire

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryant Villeponteau, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centagen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelagen, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://en.wikipedia.org/wiki/Bryant_Villeponteau</url>
    <description>Wikipedia description of Villeponteau's contributions to science and medicine</description>
  </link>
  <link>
    <url>http://www.centagen.com/index.html</url>
    <description>Centagen, Inc. Website</description>
  </link>
  <reference>
    <citation>Villeponteau B, Matsagas K, Nobles AC, Rizza C, Horwitz M, Benford G, Mockett RJ. Herbal supplement extends life span under some environmental conditions and boosts stress resistance. PLoS One. 2015 Apr 16;10(4):e0119068. doi: 10.1371/journal.pone.0119068. eCollection 2015.</citation>
    <PMID>25879540</PMID>
  </reference>
  <reference>
    <citation>Villeponteau B, Cockrell R, Feng J. Nutraceutical interventions may delay aging and the age-related diseases. Exp Gerontol. 2000 Dec;35(9-10):1405-17.</citation>
    <PMID>11113618</PMID>
  </reference>
  <reference>
    <citation>Villeponteau B. The heterochromatin loss model of aging. Exp Gerontol. 1997 Jul-Oct;32(4-5):383-94. Review.</citation>
    <PMID>9315443</PMID>
  </reference>
  <reference>
    <citation>Marus√≠c L, Anton M, Tidy A, Wang P, Villeponteau B, Bacchetti S. Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol. 1997 Nov;17(11):6394-401.</citation>
    <PMID>9343401</PMID>
  </reference>
  <reference>
    <citation>Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995 Apr;5(2):249-55. Review.</citation>
    <PMID>7613096</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Joint Instability</mesh_term>
    <mesh_term>Protein-Energy Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

